Find Therapeutics Closes $8.1 Million Financing Round
Find Therapeutics Inc., a biopharmaceutical company focused on developing innovative therapies for autoimmune diseases, has just announced the successful completion of a major financing round. This funding round raised $8.1 million in a convertible note, led by Investissement Québec, with participation from existing investors such as CTI Life Sciences Fund and adMare BioInnovations. The funds will be primarily used to advance FTX-101 into Phase 1 clinical studies.
Looking Forward to Clinical Trials
Philippe Douville, the CEO of Find Therapeutics, shared his excitement about the partnership with Investissement Québec. He pointed out how vital this investment is for fast-tracking FTX-101 into clinical stages, especially for patients in need of myelin repair therapies. Douville stated, "With the recent IND clearance from the FDA, this funding allows us to act quickly in bringing transformative therapy to those who need it."
Phase 1 Clinical Studies Overview
The Phase 1 clinical trial for FTX-101 is set to begin in the fourth quarter of this year. This trial will evaluate safety, tolerability, and pharmacokinetics across various dosage levels given to healthy volunteers. These assessments are crucial for guiding the next steps in the drug's development process.
Backing from Investissement Québec
Bicha Ngo, the President and CEO of Investissement Québec, emphasized the organization’s dedication to fostering innovative biotech companies. He recognized the importance of nurturing young firms like Find Therapeutics, explaining that their involvement is essential in addressing capital gaps. Their aim is to assist Find in launching its clinical studies while preparing the company for future growth and advancements in therapies for visual health.
FTX-101: A Closer Look
At the core of Find Therapeutics’ research is FTX-101, an innovative remyelinating agent designed to help restore vision in patients suffering from Chronic Optic Neuropathy (CON). FTX-101 functions as a therapeutic peptide that targets Plexin A1 and Neuropilin 1, both critical in the migration and differentiation of oligodendrocyte precursor cells, the essential components in forming myelin.
Preclinical Study Results
Initial preclinical studies have shown promising results for FTX-101, demonstrating its impressive ability to promote myelin repair in demyelinating animal models. This encouraging data highlights the potential effectiveness of the compound and generates optimism as the clinical trials approach.
Investissement Québec's Role in Driving Innovation
Investissement Québec is dedicated to promoting economic growth within the province through various initiatives, including fostering innovation, entrepreneurship, and competitive business practices on a global scale. By providing tailored financial solutions and strategic support, the organization plays a key role in nurturing firms at different stages of their development. Their extensive assistance includes supporting export activities and offering technological aid, aiming to uplift businesses across the province.
Find Therapeutics Background
Founded in 2020, Find Therapeutics is dedicated to developing advanced therapies for inflammatory autoimmune conditions. The company was established with investments from CTI Life Sciences and adMare BioInnovations and holds an exclusive license from Strasbourg University, based on research conducted by Dr. Dominique Bagnard. Find Therapeutics is committed to advancing next-generation medical treatments and improving patient outcomes.
Frequently Asked Questions
What exactly is FTX-101?
FTX-101 is a groundbreaking remyelinating agent developed by Find Therapeutics, aimed at restoring vision for patients with Chronic Optic Neuropathy.
How much funding has Find Therapeutics raised?
Find Therapeutics has raised $8.1 million through convertible note financing to support clinical development for FTX-101.
Which organization is leading the financing for Find Therapeutics?
The financing round is being led by Investissement Québec, with participation from existing investors including CTI Life Sciences Fund and adMare BioInnovations.
When is the Phase 1 clinical trial expected to begin?
The Phase 1 clinical trial for FTX-101 is scheduled to start in the fourth quarter of this year.
What is the goal of Investissement Québec?
Investissement Québec's mission is to promote economic development in the province by stimulating innovation, supporting entrepreneurship, and fostering investment growth.
